stockportfolio.pro
Stocks / NVCR vs SGRY
NVCR vs SGRY
NovoCure Limited and Surgery Partners, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| NovoCure Limited (NVCR) | Surgery Partners, Inc. (SGRY) | |
|---|---|---|
| Market cap | $1.9B | $1.9B |
| Revenue (latest FY) | $655.35M | $3.31B |
| Net income (latest FY) | $-136.23M | $-77.90M |
| Revenue growth (5y CAGR) | 5.8% | 12.2% |
| Net margin | -20.8% | -2.4% |
| Return on equity | -40.0% | -4.5% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 2 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open NVCR — free Open SGRY — freeFrequently asked questions
Which is bigger, NVCR or SGRY?
NovoCure Limited is larger by market capitalization — $1.9B versus $1.9B.
Which grows faster, NVCR or SGRY?
Over the last five fiscal years, Surgery Partners, Inc. grew revenue faster — 12.2%/yr versus 5.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.